

Quick Search

[Advanced Search](#)

Enter Title, Keywords, Authors, or DOI

 [Org. Lett.](#)
 [All Journals/Website](#)

 Personalize your experience: [Log In](#) | [Register](#) | [Cart](#)

Letter

Enantioselective, Ketoreductase-Based Entry into Pharmaceutical Building Blocks: Ethanol as Tunable Nicotinamide Reductant

Sylvain Broussy, Ross W. Cheloha and David B. Berkowitz*
Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588-0304

Org. Lett., Article ASAP
Publication Date (Web): December 17, 2008
Copyright © 2008 American Chemical Society

Abstract

 Full Text HTML

 Hi-Res PDF [1227 KB]

 PDF w/ Links [291 KB]

Supporting Info

[Figures](#)[References](#)

Article Tools

 Add to Favorites

 Download Citation

 Email a Colleague

 Rights & Permissions

 Citation Alerts


History

Received: October 24, 2008

Recommend & Share

 del.icio.us

 Digg This

 Facebook

 Newsvine

About Our New Website

Website Demo
Frequently Asked Questions
Comments & Suggestions?

Related Content

Other ACS articles by these authors:

Sylvain Broussy
Ross W. Cheloha
David B. Berkowitz

Abstract

The use of NADH- and NADPH-dependent ketoreductases to access enantioenriched pharmaceutical building blocks is reported. Seven structurally diverse synthons are obtained, including those for atomoxetine (KRED 132), talampanel (RS1-ADH and CPADH), Dolastatin (KRED 132), and fluoxetine (KRED 108/132). Ethanol may be used as stoichiometric reductant, regenerating both nicotinamide cofactors, particularly under four-electron redox conditions. Its favorable thermodynamic and economic profile, coupled with its advantageous dual cosolvent role, suggests a new application for biomass-derived ethanol.

















As has been pointed out in a recent overview from the Merck Process Group,⁽¹⁾ advances in ketoreductase (KRED or alcohol dehydrogenase = ADH) technology have increased their potential for process chemistry. Asymmetric enzymatic reductions, *ex vivo*, are now more easily investigated in the research laboratory and may be optimized there, under controlled conditions, offering a viable and complementary alternative to *in vivo* approaches, for example, in genetically engineered yeast⁽²⁾ or *E. coli*.⁽³⁾ The *ex vivo* system circumvents issues of substrate, product, and cosolvent toxicity, provided that enzyme activity and enantioselectivity are preserved.

We have a standing interest in the use of enzymes in asymmetric synthesis, for example, to access enantiomerically enriched podophyllum lignans⁽⁴⁾ or quaternary, α -vinyl amino acids.⁽⁵⁾ More recently, that focus has turned to ADHs, as catalytic reporting enzymes to facilitate the evaluation of organometallic catalysts via ISES (in situ enzymatic screening).^(5, 6) Parallel to these studies, we have undertaken to exploit ketoreductases in target-directed asymmetric synthesis. Indeed, the repertoire of enzymes in modern asymmetric synthesis continues to expand, including lipases,⁽⁷⁾ amidases,⁽⁸⁾ amine oxidases,⁽⁹⁾ alcohol⁽¹⁰⁾ and amine DHs,⁽¹¹⁾ epoxide hydrolases⁽¹²⁾ and aldolases,⁽¹³⁾ among others.⁽¹⁴⁾

In this work, we have focused upon an array of ketones, the asymmetric reduction of which provides valuable pharmaceutical building blocks. In Table 1, each chiral secondary alcohol product is mapped (red shading) onto the pharmaceutical for which it is a synthon. The Aprepitant-leading ketone 1 served as a model for our *ex vivo* conditions, giving high (*S*)-selectivity with CPADH and HLADH, consistent with reports from Merck⁽¹⁵⁾ and Rhodia,⁽¹⁶⁾

respectively. The second ketone screened serves as the substrate for a classic biocatalytic process (*Zygosaccharomyces rouxi* whole-cell route, Zmijewski group at Lilly(17)) for the production of Talampanel. Our screen identified two new DHs here, CPADH and RS-1 ADH, each of which also gives the correct antipode (*S*)-4, with high selectivity.

Table 1. Asymmetric Ketoreductase-Mediated Access to Pharmaceutical Building Blocks

ketone	enzyme ^a	convn ^b	ee ^c	prod config ^d	pharmaceutical target	trade name(s) (config.)	application
	HLADH ^e CPADH ^f	99% 99%	98% 98%	(<i>S</i>)-2 (<i>S</i>)-2		Emend, Aprepitant, L-754030 (<i>R</i>) <i>(S)</i> -enantiomer is a constituent of analogues in clinical trials ^g	Human neurokinin-1 (NK-1) antagonist, anti-emetic, adjuvant for cancer chemotherapy
	HLADH CPADH RS-1 ADH	99% 99% 99%	95% 99% 99%	(<i>S</i>)-4 (<i>S</i>)-4 (<i>S</i>)-4		Talampanel, LY-300164 (<i>R</i>) ^h	AMPA receptor antagonist, anti-convulsant, for the treatment of epilepsy, viral encephalophase II clinical trials, anti-cancer agent
	KRED 101 KRED 108 KRED 118 KRED 132	40% 86% 85% 83%	37% 94% 65% 98%	(<i>R</i>)-6 (<i>R</i>)-6 (<i>R</i>)-6 (<i>S</i>)-6		Dolastatin 10 (<i>R</i>)	natural product, anti-proliferative antifungal agent
	CPADH RS-1 ADH LKADH KRED 132	99% 92% 90% 94%	98% 98% 86% 98%	(<i>S</i>)-8 (<i>S</i>)-8 (<i>R</i>)-8 (<i>S</i>)-8		Dysidenin barbamide MA-20565 (<i>S</i>) ⁱ	natural product, anti-proliferative antifungal agent
	KRED 101 KRED 108 KRED 118 KRED 132	50% 40% 65% 82%	5% 7% 30% 97%	(<i>S</i>)-10 (<i>R</i>)-10 (<i>S</i>)-10 (<i>S</i>)-10		Fluoxetine, Prozac; also appl. to Strattera (<i>R</i>) or (<i>R,S</i>) ^k	serotonin reuptake inhibitor, anti-depressant
	KRED 108 KRED 118 KRED 132	85% 90% 60%	97% 80% 40%	(<i>S</i>)-12 (<i>S</i>)-12 (<i>S</i>)-12		Atomoxetine, Strattera (<i>R</i>) ^k	norepinephrine reuptake inhibitor, treatment of ADHD
	KRED 132	70%	99%	(<i>S</i>)-14		Atomoxetine, Strattera (<i>R</i>) ^k	norepinephrine reuptake inhibitor, treatment of ADHD

a Color code: NADH and NADPH enzymes in black and green, respectively.

Abbreviations: ADH = alcohol dehydrogenase from HL (horse liver), LK (*Lactobacillus kefir*), both from Sigma-Aldrich; CP (*Candida parapsilosis*), RS1 (*Rhodococcus species-1*), both from Jülich; KREDs = ketoreductases, all from Codexis.

b All substrate screening reactions were run with stoichiometric cofactor and conversion was judged by NMR (see Supporting Information for details).

c Percent ee established by chiral HPLC [Chiralcel OD or (*S,S*)-WHELK O1].

d Absolute stereochemistry established by comparison of the sign of optical rotation or relative retention time (chiral HPLC) with literature values (see Supporting Information).

e The (*S*)-selectivity of HLADH with this ketone has been observed by others (ref 16).

f The (*S*)-selectivity of CPADH with this ketone has been observed by others (ref 15).

g While Emend itself has the (*R*)-stereochemistry at the secondary alcohol center in question, Merck is investigating NK-1 receptor antagonists with the (*S*)-stereochemistry at this center (ref 15).

h Closure of the 7-ring here is via N-attack at a secondary mesylate, inverting the stereochemistry at the key center.

i The (*S*)-stereocenter of MA-205765 is set via double inversion: first, conversion of the alcohol to the (*R*)-benzylic chloride and then backside displacement with a hydroxylamine nucleophile (ref 20b).

j Even though fluoxetine is FDA-approved as the racemate, the (*R*)-antipode of the major metabolite, norfluoxetine, more effectively inhibits serotonin reuptake (ref 24).

k The (*R*)-center in both fluoxetine and atomoxetine is set via inversion of the (*S*)-alcohol, via Mitsunobu conditions with the appropriate phenolate nucleophile (ref 24).

Ketones 5 and 7 are precursors to building blocks for the promising chemotherapeutic candidate Dolastatin 10 and Mitsubishi's broad spectrum fungicide MA-20565, respectively. In the former case, Genet has reported the use of stoichiometric DIP-Cl (92% ee),(18) whereas Masui employs

a diphenylprolinol-ligated borane reagent (92% ee).⁽¹⁹⁾ The highly enantioselective reductions seen here (KREDs 108 and 132) open up alternative “green” processes. Similarly, while both Ru(II)-diamine-⁽²⁰⁾ and Rh-diamine-based⁽²¹⁾ asymmetric hydrogenations of **7** have been reported, reductions with CPADH, RS-1 ADH, and KRED 132, uncovered in these studies, provide viable biocatalytic alternatives.

The final three entries (**9**, **11**, **13**) in Table 1 are precursors to either (*R*)-Strattera or (*R*)-Fluoxetine. While there are isolated reports of whole-cell procedures for the asymmetric carbonyl reduction of **11**, either with *Saccharomyces*⁽²²⁾ or *Rhodotorula*⁽²³⁾ species, we find no previous literature descriptions of asymmetric biocatalytic reductions of either **9** or **13**. In this regard, the success we have had with KRED 132, in both cases, is quite notable. The ee's are certainly competitive with those seen using Itsuno–Corey oxazaborolidine reduction (Senanayake)⁽²⁴⁾ in the former case or Pd(II)-sparteine-mediated oxidative kinetic resolution (Stoltz)⁽²⁵⁾ in the latter.

With a half-dozen promising new DH-based asymmetric reductions in hand, we next set about to examine cofactor regeneration. The most commonly used nicotinamide-regenerating reagents, with favorable thermodynamics, are collected in Figure 1 and compared with EtOH. Note that van der Donk and Zhao⁽²⁶⁾ have recently opened the door to phosphite-based reductions, with the most favorable redox potential of the group. Although Wong and Whitesides⁽²⁷⁾ established the potential for using EtOH in biocatalytic reductions with water-soluble substrates, use of this reductant for chemoenzymatic synthesis has lagged behind. However, EtOH is attractive here in (a) having a favorable redox potential, (b) being economically priced and readily available from the biomass fermentation stream, and (c) potentially serving a dual role as organic cosolvent. Regarding the first point, employing EtOH as a four-electron reductant provides for more favorable thermodynamics, which result from the highly exergonic reduction of NAD(P) with acetaldehyde, provided that aldehyde DH (ALDH) activity is present.




Figure 1. Thermodynamics of nicotinamide cofactor regeneration; tunability of the ethanol reductant.

This tunability of the EtOH reductant was examined in a model NMR experiment (Figure 2) with KRED 132 and ketone **9**. KRED 132 requires NADPH. We have found that LKADH can effectively be used to oxidize EtOH with NADP. In our hands, yeast ALDH also efficiently utilizes NADP. So, this LKADH/YALDH couple was employed to access the full four-electron reducing capacity of EtOH (panel A) and compared with the reaction under two-electron redox conditions (no YALDH, panel B, Le Chatelier effect alone). In fact, the reduction run under four-electron reducing conditions proceeds much more rapidly. As expected, one sees the clear AcOH signature in the former case, attesting to the four electron redox cycle in play. Table 2 illustrates the use of these four electron conditions across three different substrates and four different DHs at the millimolar scale.








Figure 2. Comparison of the KRED-132-mediated reduction of ketone **9** with NADPH (2 mol %) regeneration using LKADH (50 mM KPO₄ in D₂O, pH 7.5; 300 rpm, 30 °C, 3 h), both with (panel A) and without (panel B) YALDH (see Supporting Information for details). Note the increased conversion and AcOH production under four electron reduction conditions.

Table 2. Biocatalytic Reductions at the Millimolar Scale; Ethanol as Four-Electron Reductant^a

chiral product	ADH	regen system	cofactor (mol %)	yield	ee
 (4)	CP-ADH	YADH/ YAIDH	NAD ⁺ (0.4)	89%	94% (S)
 (10)	KRED 132	LK- ADH/ YAIDH	NADP ⁺ (1)	86%	96% (S)
 (8)	RS-1 ADH	YADH/ YAIDH	NAD ⁺ (1)	98%	99% (S)
 (8)	LK- ADH	(LK- ADH)/ YAIDH	NADP ⁺ (2)	64%	86% (R)

^a All reductions were performed on a 1 mmol scale at 30 °C, 300 rpm, pH 7.5 with the cofactor regeneration systems shown. See [Supporting Information](#) for details.

In summary, the first viable ketoreductase-based entries into secondary alcohol building blocks for Dolastatin 10 (5), Prozac (9), and Strattera (13) are presented here, as are new biocatalytic entries into building blocks for Talampantel (3) and MA-20565 (7). The viability of using biomass-derived EtOH for cofactor regeneration is examined, and the advantage of using four-electron redox cycles in such processes is demonstrated. Future studies will further probe the scope, limitations, and optimal conditions for such “green” alternatives to transition metal or boron hydride based chiral carbonyl reductants for asymmetric process chemistry.

Acknowledgment

Support from the NSF (CHE-0616840), Nebraska Center for Energy Sciences Research and Nebraska UCARE (fellowship to RWC) is gratefully acknowledged. Thomas Daußmann and Pascal Dünkermann (Jülich Chiral Solutions) are thanked for providing CPADH and RS1-ADH.

Supporting Information




Details of the synthetic and enzymatic chemistry, and spectroscopic and chiral HPLC characterization of products. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

This article references 27 other publications.

- Moore, J. C.; Pollard, D. J.; Kosjek, B.; Devine, P. N. *Acc. Chem. Res.* 2007 40 1412 1419 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
- Kaluzna, I. A.; Feske, B. D.; Wittayanan, W.; Ghiviriga, I.; Stewart, J. D. *J. Org. Chem.* 2005 70 342 345 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
- (a) Li, W.; Xie, D.; Frost, J. W.; Niu, W. *J. Am. Chem. Soc.* 2005 127 2874 2882 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
(b) Draths, K. M.; Frost, J. W. *Biotechnol. Prog.* 2002 18 201 211 [[CrossRef](#)], [[PubMed](#)]
-

- (a) Berkowitz, D. B.; Choi, S.; Maeng, J.-H. *J. Org. Chem.* 2000 65 847 860 [[ACS Full Text](#) , [PubMed](#)], [[ChemPort](#)]
- (b) Berkowitz, D. B.; Hartung, R. E.; Choi, S. *Tetrahedron: Asymmetry* 1999 10 4513 4520 [[CrossRef](#)], [[ChemPort](#)]
- (c) Berkowitz, D. B.; Maeng, J.-H.; Dantzig, A. H.; Shepard, R. L.; Norman, B. H. *J. Am. Chem. Soc.* 1996 118 9426 9427 [[ACS Full Text](#) , [[ChemPort](#)]
5. Berkowitz, D. B.; Pumphrey, J. A.; Shen, Q. *Tetrahedron Lett.* 1994 35 8743 8746 [[CrossRef](#)], [[ChemPort](#)]
6. (a) Dey, S.; Powell, D. R.; Hu, C.; Berkowitz, D. B. *Angew. Chem., Int. Ed.* 2007 46 7010 7014 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
- (b) Dey, S.; Karukurichi, K. R.; Shen, W.; Berkowitz, D. B. *J. Am. Chem. Soc.* 2005 127 8610 8611 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
- (c) Berkowitz, D. B.; Maiti, G. *Org. Lett.* 2004 6 2661 2664 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
- (d) Berkowitz, D. B.; Bose, M.; Choi, S. *Angew. Chem., Int. Ed.* 2002 41 1603 1607 [[CrossRef](#)], [[ChemPort](#)]
7. (a) Fluxa, V. S.; Wahler, D.; Reymond, J.-L. *Nat. Protoc.* 2008 3 1270 1277 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
- (b) Boettcher, D.; Bornscheuer, U. T. *Nat. Protoc.* 2006 1 2340 2343 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
- (c) Reetz, M. T.; Bocola, M.; Carballeira, J. D.; Zha, D.; Vogel, A. *Angew. Chem., Int. Ed.* 2005 44 4192 4196 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
- Qian, Z.; Lutz, S. *J. Am. Chem. Soc.* 2005 127 13466 13467 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
8. Savile, C. K.; Magloire, V. P.; Kazlauskas, R. J. *J. Am. Chem. Soc.* 2005 127 2104 2113 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
9. Dunsmore, C. J.; Carr, R.; Fleming, T.; Turner, N. J. *J. Am. Chem. Soc.* 2006 128 2224 2225 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
10. (a) Zhu, D.; Yang, Y.; Majkowicz, S.; Pan, T. H.-Y.; Kantardjieff, K.; Hua, L. *Org. Lett.* 2008 10 525 528 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
- (b) Zhu, D.; Ankati, H.; Mukherjee, C.; Yang, Y.; Biehl, E. R.; Hua, L. *Org. Lett.* 2007 9 2561 2563 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
- (c) Voss, C. V.; Gruber, C. C.; Kroutil, W. *Angew. Chem., Int. Ed.* 2008 47 741 745 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
- (d) Kalaitzakis, D.; Rozzell, J. D.; Kambourakis, S.; Smonou, I. *Org. Lett.* 2005 7 4799 4801 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
11. Hummel, W.; Kuzu, M.; Geueke, B. *Org. Lett.* 2003 5 3649 3650 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
12. (a) Bottalla, A.-L.; Ibrahim-Ouali, M.; Santelli, M.; Furstoss, R.; Archelas, A. *Adv. Synth. Catal.* 2007 349 1102 1110 [[CrossRef](#)], [[ChemPort](#)]
- (b) Reetz, M. T.; Wang, L.-W.; Bocola, M. *Angew. Chem., Int. Ed.* 2006 45 1236 1241 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
- (c) Edegger, K.; Mayer, S. F.; Steinreiber, A.; Faber, K. *Tetrahedron* 2004 60 583 588 [[CrossRef](#)], [[ChemPort](#)]
13. Dean, S. M.; Greenberg, W. A.; Wong, C.-H. *Adv. Synth. Catal.* 2007 349 1308 1320 [[CrossRef](#)], [[ChemPort](#)]
14. Voelkert, M.; Koul, S.; Mueller, G. H.; Lehnig, M.; Waldmann, H. *J. Org. Chem.* 2002 67 6902 6910 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
15. Pollard, D.; Truppo, M.; Pollard, J.; Chen, C.-Y.; Moore, J. *Tetrahedron: Asymmetry* 2006 17 554 559 [[CrossRef](#)], [[ChemPort](#)]
- 16.

- Gelo-Pujic, M.; Le Guyader, F.; Schlama, T. *Tetrahedron: Asymmetry* 2006 17 2000 2005 [[CrossRef](#)], [[ChemPort](#)]
17. Anderson, B. A.; Hansen, M. M.; Harkness, A. R.; Henry, C. L.; Vicenzi, J. T.; Zmijewski, M. J. *J. Am. Chem. Soc.* 1995 117 12358 12359 [[ACS Full Text](#) , [[ChemPort](#)]
18. Mordant, C.; Reymond, S.; Tone, H.; Lavergne, D.; Touati, R.; Ben Hassine, B.; Ratovelomanana-Vidal, V.; Genet, J.-P. *Tetrahedron* 2007 63 6115 6123 [[CrossRef](#)], [[ChemPort](#)]
19. Masui, M.; Shioiri, T. *Synlett* 1997 273 274 [[CrossRef](#)]
20. (a) Ahlford, K.; Zaitsev, A. B.; Ekstroem, J.; Adolfsson, H. *Synlett* 2007 2541 2544
(b) Tanaka, K.; Katsurada, M.; Ohno, F.; Shiga, Y.; Oda, M.; Miyagi, M.; Takehara, J.; Okano, K. *J. Org. Chem.* 2000 65 432 437 [[ACS Full Text](#) , [[PubMed](#)], [[ChemPort](#)]
21. Matharu, D. S.; Morris, D. J.; Clarkson, G. J.; Wills, M. *Chem. Commun.* 2006 3232 3234 [[CrossRef](#)]
22. (a) Ou, Z.; Wu, J.; Yang, L.; Cen, P. *Kor. J. Chem. Eng.* 2008 25 124 128 [[CrossRef](#)], [[ChemPort](#)]
(b) Fronza, G.; Fuganti, C.; Grasselli, P.; Mele, A. *J. Org. Chem.* 1991 56 6019 6023 [[ACS Full Text](#) , [[ChemPort](#)]
23. Yang, W.; Xu, J.-H.; Xie, Y.; Xu, Y.; Zhao, G.; Lin, G.-Q. *Tetrahedron: Asymmetry* 2006 17 1769 1774 [[CrossRef](#)], [[ChemPort](#)]
24. Hilborn, J. W.; Lu, Z.-H.; Jurgens, A. R.; Fang, Q. K.; Byers, P.; Wald, S. A.; Senanayake, C. H. *Tetrahedron Lett.* 2001 42 8919 8921 [[CrossRef](#)], [[ChemPort](#)]
25. Caspi, D. D.; Ebner, D. C.; Bagdanoff, J. T.; Stoltz, B. M. *Adv. Synth. Catal.* 2004 346 185 189 [[CrossRef](#)], [[ChemPort](#)]
26. Woodyer, R.; Zhao, H.; van der Donk, W. A. *FEBS J.* 2005 272 3816 27 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
27. Wong, C. H.; Whitesides, G. M. *J. Am. Chem. Soc.* 1983 105 5012 14 [[ACS Full Text](#) , [[ChemPort](#)]